Seelos Therapeutics, Inc. (SEEL): Price and Financial Metrics


Seelos Therapeutics, Inc. (SEEL): $0.81

0.00 (-0.14%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SEEL to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

SEEL Stock Price Chart Interactive Chart >

Price chart for SEEL

SEEL Price/Volume Stats

Current price $0.81 52-week high $1.52
Prev. close $0.81 52-week low $0.48
Day low $0.80 Volume 187,400
Day high $0.83 Avg. volume 460,881
50-day MA $0.88 Dividend yield N/A
200-day MA $0.87 Market Cap 86.91M

Seelos Therapeutics, Inc. (SEEL) Company Bio


Seelos Therapeutics, Inc. operates as a biotechnology company. The Company develops treatments for post-traumatic stress and major depressive disorders. Seelos Therapeutics serves patients in the United States.


SEEL Latest News Stream


Event/Time News Detail
Loading, please wait...

SEEL Latest Social Stream


Loading social stream, please wait...

View Full SEEL Social Stream

Latest SEEL News From Around the Web

Below are the latest news stories about SEELOS THERAPEUTICS INC that investors may wish to consider to help them evaluate SEEL as an investment opportunity.

Seelos Therapeutics to Participate in the 12th Annual LifeSci Partners Corporate Access Event

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in the 12th Annual LifeSci Partners Corporate Access Event, to be held in San Francisco, California on January 9-11th, 2023.

Yahoo | December 22, 2022

Parkinson's Study Using CRISPR Technology Shows Promise, Seelos Therapeutics Says

Seelos Therapeutics Inc (NASDAQ: SEEL) announced in vivo data demonstrating that a single dose of SLS-004 downregulated the production of alpha-synuclein (α-synuclein). This reduction of α-synuclein by SLS-004 in an established α-synuclein overexpressing animal model of Parkinson's disease (PD) resulted in a substantial increase and recovery of degeneration in tyrosine hydroxylase positive (TH+) dopaminergic neurons. TH+ dopaminergic neurons in the midbrain region, called substantia nigra pars c

Yahoo | December 15, 2022

Seelos Therapeutics Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced in vivo data demonstrating that a single dose of SLS-004 downregulated the production of alpha-synuclein (α-synuclein). This reduction of α-synuclein by SLS-004 in an established α-synuclein overexpressing animal model of Parkinson's disease (PD) resulted in substantial increase and recovery of degener

Yahoo | December 15, 2022

Seelos Therapeutics Releases the Itinerary for its Research and Development Update Conference Call and Webcast to be Held on December 15, 2022

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today released the itinerary for its research and development update conference call and webcast to be held on Thursday, December 15th from 1pm to 3pm ET.

Yahoo | December 8, 2022

Seelos Therapeutics to Hold a Research and Development Update Conference Call and Webcast on December 15, 2022

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will hold a research and development update conference call and webcast on Thursday, December 15th from 1pm to 3pm ET.

Yahoo | November 23, 2022

Read More 'SEEL' Stories Here

SEEL Price Returns

1-mo 17.39%
3-mo -7.68%
6-mo -18.99%
1-year -28.95%
3-year -17.35%
5-year -98.78%
YTD 19.29%
2022 -58.34%
2021 3.16%
2020 17.91%
2019 -76.74%
2018 -89.57%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6467 seconds.